Why the study?
To discuss the basic pharmacology, clinical efficacy, safety, and future perspectives of angiotensin II as an add-on vasopressor in vasodilatory shock.
Does Angiotensin II improve outcomes in patients with vasodilatory shock?
Does Angiotensin II improve outcomes in patients with vasodilatory shock?
Angiotensin II is an effective add-on vasopressor for increasing blood pressure and sparing catecholamines in vasodilatory shock.
Answers are grounded in this paper and cite their sources.
May support catecholamine-sparing BP control in vasodilatory shock; leaves open effects on mortality and need for RCTs.
Shock is an acute condition of circulatory failure resulting in life-threatening organ dysfunction, high morbidity and high mortality. Current management includes fluid and catecholamine therapy to maintain adequate mean arterial pressure and organ perfusion. Norepinephrine is recommended as first-line vasopressor, but other agents are available. Angiotensin II is an alternative potent vasoconstrictor without chronotropic or inotropic properties. Several studies, including a large randomized controlled trial have demonstrated its ability to increase blood pressure with catecholamine-sparing effects. Angiotensin II was consequently approved by the US FDA in 2017 and the EU in 2019 as an add-on vasopressor in vasodilatory shock. This review aims to discuss its basic pharmacology, clinical efficacy, safety and future perspectives.
No takes yet. Share an insight, caveat, or question.
Lumlertgul et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: